In recent years, interleukin 2 (IL-2) has been suggested to play a key role in MS etiopathogenesis by regulating immune cell responses, and its elevated expression in Th17 lymphocytes, along with other factors promoting inflammation, could be related to high inflammatory status [9]. Here, IL2 is linked to myeloid sarcoma.